{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:10:05Z","timestamp":1787987405982,"version":"build-2784847793"},"reference-count":44,"publisher":"Harborside Press, LLC","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Patients with sarcopenia and elevated body mass index (BMI) are at high risk of platinum-associated adverse events (AEs). This study examines the association between sarcopenia, BMI, and AEs in patients with non\u2013small cell lung cancer (NSCLC).\n                    <jats:bold>Methods:<\/jats:bold>\n                    This retrospective cohort study included adult patients with NSCLC who started cisplatin or carboplatin between 2015 and 2022. Sarcopenia was defined on CT using sex-specific cutoffs for skeletal muscle index. We evaluated the association between CT-defined sarcopenia and grade \u22652 AEs (including anemia, thrombocytopenia, neutropenia, and increased creatinine), chemotherapy discontinuation, and 90-day mortality in patients with normal (&lt;25 kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) and elevated (\u226525 kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) BMI using a Fine-Gray subdistribution hazard model. The association between receiving an excess carboplatin dose and AEs was evaluated.\n                    <jats:bold>Results:<\/jats:bold>\n                    Of 604 included patients, the mean [SD] age was 66 [10] years, 307 (51%) were female, and 167 (28%) had sarcopenia. Sarcopenia and elevated BMI (n=67) was associated with an increased risk of grade \u22652 anemia (subdistribution hazard ratio [sHR], 1.64; 95% CI, 1.17\u20132.29;\n                    <jats:italic>P<\/jats:italic>\n                    =.004), thrombocytopenia (sHR, 2.25; 95% CI, 1.16\u20134.36;\n                    <jats:italic>P<\/jats:italic>\n                    =.016), and increased creatinine (sHR, 2.72; 95% CI, 1.45\u20135.13;\n                    <jats:italic>P<\/jats:italic>\n                    =.002). Sensitivity analyses demonstrated that patients whose Cockcroft-Gault\u2013based glomerular filtration rate (GFR) dictated a carboplatin dose \u226525 mg higher than CKD-EPI GFR were at significantly higher risk of grade \u22652 AEs and chemotherapy discontinuation.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Combined CT-defined sarcopenia with elevated BMI is associated with an increased risk of platinum-associated AEs in patients with NSCLC; this may be due to GFR misestimation in patients with low muscle mass and elevated BMI.\n                  <\/jats:p>","DOI":"10.6004\/jnccn.2025.7048","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T14:07:19Z","timestamp":1753884439000},"page":"393-400","source":"Crossref","is-referenced-by-count":6,"title":["Sarcopenia, Elevated Body Mass Index, and Platinum-Associated Adverse Events in Patients With Lung Cancer"],"prefix":"10.6004","volume":"23","author":[{"given":"Jiaxuan","family":"Lyu","sequence":"first","affiliation":[{"name":"MMSCI Program, Harvard Medical School, Boston MA"},{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston MA"},{"name":"Department of Nephrology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Mantz","sequence":"additional","affiliation":[{"name":"Department of Radiology, Massachusetts General Hospital, Boston, MA"},{"name":"Department of Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurit S.","family":"Katz-Agranov","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston MA"},{"name":"Renal Section, VA Boston Healthcare System, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Hanna","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston MA"},{"name":"Division of Nephrology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherley M.","family":"Mejia","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiana","family":"Moreno","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Cao","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Dinulos","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duru","family":"Cosar","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Shaker","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Center for Aging and Serious Illness, Massachusetts General Hospital, Boston MA"},{"name":"Division of General Internal Medicine, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin F.","family":"Gainor","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Temel","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley A.","family":"Inker","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian J.","family":"Fintelmann","sequence":"additional","affiliation":[{"name":"Department of Radiology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan E.","family":"Sise","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"J Cancer Res Clin Oncol","first-page":"1629","article-title":"Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy?","volume":"142","author":"Kato T","year":"2016","unstructured":"Kato T, Morise M, Ando M,  Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy? J Cancer Res Clin Oncol 2016;142:1629\u20131640."},{"key":"B2","series-title":"Kidney Int","first-page":"607","article-title":"A prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors","volume":"101","author":"Costa E Silva VT","year":"2022","unstructured":"Costa E Silva VT, Gil LA, Inker LA,  A prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors. Kidney Int 2022;101:607\u2013614."},{"key":"B3","series-title":"Clin J Am Soc Nephrol","first-page":"587","article-title":"Estimation of kidney function in oncology: implications for anticancer drug selection and dosing","volume":"14","author":"Casal MA","year":"2019","unstructured":"Casal MA, Nolin TD, Beumer JH. Estimation of kidney function in oncology: implications for anticancer drug selection and dosing. Clin J Am Soc Nephrol 2019;14:587\u2013595."},{"key":"B4","series-title":"Aging Clin Exp Res","first-page":"1747","article-title":"Older cancer patients receiving radiotherapy: a systematic review for the role of sarcopenia in treatment outcomes","volume":"34","author":"Catikkas NM","year":"2022","unstructured":"Catikkas NM, Bahat Z, Oren MM, Bahat G. Older cancer patients receiving radiotherapy: a systematic review for the role of sarcopenia in treatment outcomes. Aging Clin Exp Res 2022;34:1747\u20131759."},{"key":"B5","series-title":"Breast","first-page":"84","article-title":"Is sarcopenia a missed factor in the management of patients with metastatic breast cancer?","volume":"61","author":"Deluche E","year":"2022","unstructured":"Deluche E, Lachatre D, Di Palma M,  Is sarcopenia a missed factor in the management of patients with metastatic breast cancer? Breast 2022;61:84\u201390."},{"key":"B6","series-title":"Radiology","first-page":"645","article-title":"Association of adipopenia at preoperative PET\/CT with mortality in stage I non-small cell lung cancer","volume":"301","author":"Choi H","year":"2021","unstructured":"Choi H, Park YS, Na KJ,  Association of adipopenia at preoperative PET\/CT with mortality in stage I non-small cell lung cancer. Radiology 2021;301:645\u2013653."},{"key":"B7","series-title":"Lung Cancer","first-page":"92","article-title":"Clinical implications of sarcopenia in patients undergoing complete resection for early non-small cell lung cancer","volume":"101","author":"Suzuki Y","year":"2016","unstructured":"Suzuki Y, Okamoto T, Fujishita T,  Clinical implications of sarcopenia in patients undergoing complete resection for early non-small cell lung cancer. Lung Cancer 2016;101:92\u201397."},{"key":"B8","series-title":"Discov Oncol","first-page":"115","article-title":"Impact of sarcopenia on the prognosis and treatment of lung cancer: an umbrella review","volume":"13","author":"Lin TY","year":"2022","unstructured":"Lin TY, Chen YF, Wu WT,  Impact of sarcopenia on the prognosis and treatment of lung cancer: an umbrella review. Discov Oncol 2022;13:115."},{"key":"B9","series-title":"J Thorac Oncol","first-page":"1478","article-title":"Obesity paradox in lung cancer prognosis: evolving biological insights and clinical implications","volume":"12","author":"Zhang X","year":"2017","unstructured":"Zhang X, Liu Y, Shao H, Zheng X. Obesity paradox in lung cancer prognosis: evolving biological insights and clinical implications. J Thorac Oncol 2017;12:1478\u20131488."},{"key":"B10","series-title":"Lung Cancer","first-page":"52","article-title":"Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC)","volume":"104","author":"Lam VK","year":"2017","unstructured":"Lam VK, Bentzen SM, Mohindra P,  Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC). Lung Cancer 2017;104:52\u201357."},{"key":"B11","series-title":"J Thorac Oncol","first-page":"895","article-title":"Sarcopenia in resected NSCLC: effect on postoperative outcomes","volume":"13","author":"Nakamura R","year":"2018","unstructured":"Nakamura R, Inage Y, Tobita R,  Sarcopenia in resected NSCLC: effect on postoperative outcomes. J Thorac Oncol 2018;13:895\u2013903."},{"key":"B12","series-title":"J Thorac Oncol","first-page":"1294","article-title":"Predictors of physical and functional loss in advanced-stage lung cancer patients receiving platinum chemotherapy","volume":"13","author":"Kinsey E","year":"2018","unstructured":"Kinsey E, Ajazi E, Wang X,  Predictors of physical and functional loss in advanced-stage lung cancer patients receiving platinum chemotherapy. J Thorac Oncol 2018;13:1294\u20131301."},{"key":"B13","series-title":"Lung Cancer","first-page":"85","article-title":"Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer","volume":"90","author":"Sjoblom B","year":"2015","unstructured":"Sjoblom B, Gronberg BH, Benth JS,  Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer. Lung Cancer 2015;90:85\u201391."},{"key":"B14","series-title":"Nephron","first-page":"31","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft DW","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31\u201341."},{"key":"B15","series-title":"N Engl J Med","first-page":"1737","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker LA","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J,  New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med 2021;385:1737\u20131749."},{"key":"B16","series-title":"Sci Rep","first-page":"11369","article-title":"Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population","volume":"8","author":"Derstine BA","year":"2018","unstructured":"Derstine BA, Holcombe SA, Ross BE,  Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. Sci Rep 2018;8:11369."},{"key":"B17","series-title":"Invest Radiol","first-page":"259","article-title":"Muscle reference values from thoracic and abdominal CT for sarcopenia assessment: the Framingham Heart Study","volume":"59","author":"Tonnesen PE","year":"2024","unstructured":"Tonnesen PE, Mercaldo ND, Tahir I,  Muscle reference values from thoracic and abdominal CT for sarcopenia assessment: the Framingham Heart Study. Invest Radiol 2024;59:259\u2013270."},{"key":"B18","series-title":"Radiol Artif Intell","first-page":"e210080","article-title":"A fully automated deep learning pipeline for multi-vertebral level quantification and characterization of muscle and adipose tissue on chest CT scans","volume":"4","author":"Bridge CP","year":"2022","unstructured":"Bridge CP, Best TD, Wrobel MM,  A fully automated deep learning pipeline for multi-vertebral level quantification and characterization of muscle and adipose tissue on chest CT scans. Radiol Artif Intell 2022;4:e210080."},{"key":"B19","series-title":"J Cachexia Sarcopenia Muscle","first-page":"190","article-title":"Percentile-based averaging and skeletal muscle gauge improve body composition analysis: validation at multiple vertebral levels","volume":"13","author":"Marquardt JP","year":"2022","unstructured":"Marquardt JP, Roeland EJ, Van Seventer EE,  Percentile-based averaging and skeletal muscle gauge improve body composition analysis: validation at multiple vertebral levels. J Cachexia Sarcopenia Muscle 2022;13:190\u2013202."},{"key":"B20","series-title":"J Clin Oncol","first-page":"682","article-title":"Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin","volume":"36","author":"Motwani SS","year":"2018","unstructured":"Motwani SS, McMahon GM, Humphreys BD,  Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin. J Clin Oncol 2018;36:682\u2013688."},{"key":"B21","series-title":"Br J Cancer","first-page":"1199","article-title":"Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients","volume":"88","author":"de Jongh FE","year":"2003","unstructured":"de Jongh FE, van Veen RN, Veltman SJ,  Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 2003;88:1199\u20131206."},{"key":"B22","series-title":"Cancer Treat Rev","first-page":"243","article-title":"Impact of aging on the risk of platinum-related renal toxicity: a systematic review and meta-analysis","volume":"69","author":"Duan ZY","year":"2018","unstructured":"Duan ZY, Liu JQ, Yin P,  Impact of aging on the risk of platinum-related renal toxicity: a systematic review and meta-analysis. Cancer Treat Rev 2018;69:243\u2013253."},{"key":"B23","series-title":"J Clin Oncol","first-page":"3733","article-title":"Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure","volume":"19","author":"de Jongh FE","year":"2001","unstructured":"de Jongh FE, Verweij J, Loos WJ,  Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001;19:3733\u20133739."},{"key":"B24","series-title":"BMJ","first-page":"e077169","article-title":"Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study","volume":"384","author":"Gupta S","year":"2024","unstructured":"Gupta S, Glezerman IG, Hirsch JS,  Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study. BMJ 2024;384:e077169."},{"key":"B25","series-title":"Lancet","first-page":"1819","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok TSK","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I,  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019;393:1819\u20131830."},{"key":"B26","series-title":"Am J Clin Nutr","first-page":"1133S","article-title":"Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis","volume":"91","author":"Baracos VE","year":"2010","unstructured":"Baracos VE, Reiman T, Mourtzakis M,  Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr 2010;91:1133S\u20131137."},{"key":"B27","series-title":"J Cachexia Sarcopenia Muscle","first-page":"1554","article-title":"The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients","volume":"13","author":"de Jong C","year":"2022","unstructured":"de Jong C, Chargi N, Herder GJM,  The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients. J Cachexia Sarcopenia Muscle 2022;13:1554\u20131564."},{"key":"B28","series-title":"Cancer Med","first-page":"7964","article-title":"Sarcopenia and adverse health-related outcomes: an umbrella review of meta-analyses of observational studies","volume":"9","author":"Xia L","year":"2020","unstructured":"Xia L, Zhao R, Wan Q,  Sarcopenia and adverse health-related outcomes: an umbrella review of meta-analyses of observational studies. Cancer Med 2020;9:7964\u20137978."},{"key":"B29","series-title":"Int J Clin Oncol","first-page":"158","article-title":"Sarcopenia as a significant predictive factor of neutropenia and overall survival in urothelial carcinoma patients underwent gemcitabine and cisplatin or carboplatin","volume":"25","author":"Yumioka T","year":"2020","unstructured":"Yumioka T, Honda M, Nishikawa R,  Sarcopenia as a significant predictive factor of neutropenia and overall survival in urothelial carcinoma patients underwent gemcitabine and cisplatin or carboplatin. Int J Clin Oncol 2020;25:158\u2013164."},{"key":"B30","series-title":"J Natl Compr Canc Netw","first-page":"319","article-title":"Associations of skeletal muscle with symptom burden and clinical outcomes in hospitalized patients with advanced cancer","volume":"19","author":"van Seventer E","year":"2021","unstructured":"van Seventer E, Marquardt JP, Troschel AS,  Associations of skeletal muscle with symptom burden and clinical outcomes in hospitalized patients with advanced cancer. J Natl Compr Canc Netw 2021;19:319\u2013327."},{"key":"B31","series-title":"Anticancer Res","first-page":"4603","article-title":"Sarcopenia as prognostic factor in lung cancer patients: a systematic review and meta-analysis","volume":"39","author":"Buentzel J","year":"2019","unstructured":"Buentzel J, Heinz J, Bleckmann A,  Sarcopenia as prognostic factor in lung cancer patients: a systematic review and meta-analysis. Anticancer Res 2019;39:4603\u20134612."},{"key":"B32","series-title":"Cancer Chemother Pharmacol","first-page":"105","article-title":"Population pharmacokinetics of cisplatin in adult cancer patients","volume":"54","author":"de Jongh FE","year":"2004","unstructured":"de Jongh FE, Gallo JM, Shen M,  Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemother Pharmacol 2004;54:105\u2013112."},{"key":"B33","series-title":"Cancer Chemother Pharmacol","first-page":"301","article-title":"Population pharmacokinetics of cisplatin in small cell lung cancer patients guided with informative priors","volume":"90","author":"Aguiar Zdovc J","year":"2022","unstructured":"Aguiar Zdovc J, Vaupoti\u010d M, Marolt G,  Population pharmacokinetics of cisplatin in small cell lung cancer patients guided with informative priors. Cancer Chemother Pharmacol 2022;90:301\u2013313."},{"key":"B34","series-title":"JAMA Netw Open","first-page":"e2321715","article-title":"Medication-related adverse events and discordancies in cystatin C-based vs serum creatinine-based estimated glomerular filtration rate in patients with cancer","volume":"6","author":"Hanna PE","year":"2023","unstructured":"Hanna PE, Wang Q, Strohbehn IA,  Medication-related adverse events and discordancies in cystatin C-based vs serum creatinine-based estimated glomerular filtration rate in patients with cancer. JAMA Netw Open 2023;6:e2321715."},{"key":"B35","series-title":"Br J Clin Pharmacol","first-page":"349","article-title":"Creatinine-based equations for the adjustment of drug dosage in an obese population","volume":"81","author":"Bouquegneau A","year":"2016","unstructured":"Bouquegneau A, Vidal-Petiot E, Moranne O,  Creatinine-based equations for the adjustment of drug dosage in an obese population. Br J Clin Pharmacol 2016;81:349\u2013361."},{"key":"B36","series-title":"Lancet Oncol","first-page":"629","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado CM","year":"2008","unstructured":"Prado CM, Lieffers JR, McCargar LJ,  Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008;9:629\u2013635."},{"key":"B37","series-title":"Clin Lung Cancer","first-page":"e129","article-title":"Drug dose per kilogram lean body mass predicts hematologic toxicity from carboplatin-doublet chemotherapy in advanced non-small-cell lung cancer","volume":"18","author":"Sj\u00f8blom B","year":"2017","unstructured":"Sj\u00f8blom B, Benth J, Gr\u00f8nberg BH,  Drug dose per kilogram lean body mass predicts hematologic toxicity from carboplatin-doublet chemotherapy in advanced non-small-cell lung cancer. Clin Lung Cancer 2017;18:e129\u2013136."},{"key":"B38","series-title":"Clin Oncol (R Coll Radiol)","first-page":"576","article-title":"Prediction of 90 day and overall survival after chemoradiotherapy for lung cancer: role of performance status and body composition","volume":"29","author":"Bowden JCS","year":"2017","unstructured":"Bowden JCS, Williams LJ, Simms A,  Prediction of 90 day and overall survival after chemoradiotherapy for lung cancer: role of performance status and body composition. Clin Oncol (R Coll Radiol) 2017;29:576\u2013584."},{"key":"B39","series-title":"Nutrients","first-page":"2212","article-title":"Impact of sarcopenia on acute kidney injury after infrarenal abdominal aortic aneurysm surgery: a propensity matching analysis","volume":"13","author":"Bang JY","year":"2021","unstructured":"Bang JY, Jun IG, Lee JB,  Impact of sarcopenia on acute kidney injury after infrarenal abdominal aortic aneurysm surgery: a propensity matching analysis. Nutrients 2021;13:2212."},{"key":"B40","series-title":"Cancer Med","first-page":"6677","article-title":"Sarcopenia on preoperative chest computed tomography predicts cancer-specific and all-cause mortality following pneumonectomy for lung cancer: a multicenter analysis","volume":"10","author":"Troschel FM","year":"2021","unstructured":"Troschel FM, Jin Q, Eichhorn F,  Sarcopenia on preoperative chest computed tomography predicts cancer-specific and all-cause mortality following pneumonectomy for lung cancer: a multicenter analysis. Cancer Med 2021;10:6677\u20136686."},{"key":"B41","series-title":"Oncologist","first-page":"514","article-title":"Temporal trends and outcomes among patients admitted for immune-related adverse events: a single-center retrospective cohort study from 2011 to 2018","volume":"26","author":"Molina GE","year":"2021","unstructured":"Molina GE, Zubiri L, Cohen JV,  Temporal trends and outcomes among patients admitted for immune-related adverse events: a single-center retrospective cohort study from 2011 to 2018. Oncologist 2021;26:514\u2013522."},{"key":"B42","series-title":"Clin J Am Soc Nephrol","first-page":"1692","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy H","year":"2019","unstructured":"Seethapathy H, Zhao S, Chute DF,  The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol 2019;14:1692\u20131700."},{"key":"B43","series-title":"Oncologist","first-page":"584","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"24","author":"Davis EJ","year":"2019","unstructured":"Davis EJ, Salem JE, Young A,  Hematologic complications of immune checkpoint inhibitors. Oncologist 2019;24:584\u2013588."},{"key":"B44","series-title":"Lancet Haematol","first-page":"e48","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy N","year":"2019","unstructured":"Delanoy N, Michot JM, Comont T,  Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 2019;6:e48\u201357."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/9\/article-p393.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/9\/article-p393.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/9\/article-p393.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T12:25:55Z","timestamp":1757507155000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/9\/article-p393.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":44,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7048","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}